therapeutic frontiers limited
therapeutic frontiers limited Company Information
Company Number
09029209
Website
-Registered Address
18 field lane, london, TW11 9AW
Industry
Research and experimental development on biotechnology
Telephone
-
Next Accounts Due
June 2024
Group Structure
View All
Directors
Ross Walton10 Years
Shareholders
ross peter walton 41.7%
cathryn macrae 32.5%
View Alltherapeutic frontiers limited Estimated Valuation
Pomanda estimates the enterprise value of THERAPEUTIC FRONTIERS LIMITED at £946.1k based on a Turnover of £1.1m and 0.87x industry multiple (adjusted for size and gross margin).
therapeutic frontiers limited Estimated Valuation
Pomanda estimates the enterprise value of THERAPEUTIC FRONTIERS LIMITED at £0 based on an EBITDA of £-323k and a 3.67x industry multiple (adjusted for size and gross margin).
therapeutic frontiers limited Estimated Valuation
Pomanda estimates the enterprise value of THERAPEUTIC FRONTIERS LIMITED at £0 based on Net Assets of £-41.2k and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Therapeutic Frontiers Limited Overview
Therapeutic Frontiers Limited is a dissolved company that was located in london, TW11 9AW with a Companies House number of 09029209. It operated in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in May 2014, it's largest shareholder was ross peter walton with a 41.7% stake. The last turnover for Therapeutic Frontiers Limited was estimated at £1.1m.
Upgrade for unlimited company reports & a free credit check
Therapeutic Frontiers Limited Health Check
Pomanda's financial health check has awarded Therapeutic Frontiers Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
2 Strong
1 Regular
6 Weak
Size
annual sales of £1.1m, make it smaller than the average company (£2.1m)
- Therapeutic Frontiers Limited
£2.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 29%, show it is growing at a faster rate (11.6%)
- Therapeutic Frontiers Limited
11.6% - Industry AVG
Production
with a gross margin of 27%, this company has a higher cost of product (51.3%)
- Therapeutic Frontiers Limited
51.3% - Industry AVG
Profitability
an operating margin of -29.6% make it less profitable than the average company (-5.8%)
- Therapeutic Frontiers Limited
-5.8% - Industry AVG
Employees
with 5 employees, this is below the industry average (39)
- Therapeutic Frontiers Limited
39 - Industry AVG
Pay Structure
on an average salary of £67.4k, the company has an equivalent pay structure (£67.4k)
- Therapeutic Frontiers Limited
£67.4k - Industry AVG
Efficiency
resulting in sales per employee of £218k, this is more efficient (£117k)
- Therapeutic Frontiers Limited
£117k - Industry AVG
Debtor Days
it gets paid by customers after 100 days, this is later than average (60 days)
- Therapeutic Frontiers Limited
60 days - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Therapeutic Frontiers Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Therapeutic Frontiers Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Therapeutic Frontiers Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 113.7%, this is a higher level of debt than the average (56.6%)
113.7% - Therapeutic Frontiers Limited
56.6% - Industry AVG
THERAPEUTIC FRONTIERS LIMITED financials
Therapeutic Frontiers Limited's latest turnover from March 2021 is estimated at £1.1 million and the company has net assets of -£41.2 thousand. According to their latest financial statements, we estimate that Therapeutic Frontiers Limited has 5 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|
| Turnover | |||||||
| Other Income Or Grants | |||||||
| Cost Of Sales | |||||||
| Gross Profit | |||||||
| Admin Expenses | |||||||
| Operating Profit | |||||||
| Interest Payable | |||||||
| Interest Receivable | |||||||
| Pre-Tax Profit | |||||||
| Tax | |||||||
| Profit After Tax | |||||||
| Dividends Paid | |||||||
| Retained Profit | |||||||
| Employee Costs | |||||||
| Number Of Employees | 3 | 3 | |||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 85,600 | 85,600 | 107,000 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 85,600 | 85,600 | 107,000 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 301,231 | 222,470 | 222,470 | 217,702 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 24,792 | 75,893 | 0 | 0 |
| Cash | 0 | 0 | 0 | 442,244 | 900,076 | 2,148 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 301,231 | 222,470 | 222,470 | 684,738 | 975,969 | 2,148 | 0 |
| total assets | 301,231 | 308,070 | 308,070 | 791,738 | 975,969 | 2,148 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 16,264 | 16,264 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 642,774 | 973,704 | 0 | 0 |
| total current liabilities | 0 | 16,264 | 16,264 | 642,774 | 973,704 | 0 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 342,473 | 10,000 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 20,330 | 0 | 0 | 0 |
| total long term liabilities | 342,473 | 10,000 | 10,000 | 20,330 | 0 | 0 | 0 |
| total liabilities | 342,473 | 26,264 | 26,264 | 663,104 | 973,704 | 0 | 0 |
| net assets | -41,242 | 281,806 | 281,806 | 128,634 | 2,265 | 2,148 | 0 |
| total shareholders funds | -41,242 | 281,806 | 281,806 | 128,634 | 2,265 | 2,148 | 0 |
| Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Operating Profit | |||||||
| Depreciation | 0 | 26,524 | 0 | 0 | |||
| Amortisation | 0 | 0 | 0 | 0 | |||
| Tax | |||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 78,761 | 0 | -20,024 | 166,601 | 75,893 | 0 | 0 |
| Creditors | -16,264 | 0 | 16,264 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 332,473 | 10,000 | -642,774 | -330,930 | 973,704 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | -20,330 | 20,330 | 0 | 0 | 0 |
| Cash flow from operations | |||||||
| Investing Activities | |||||||
| capital expenditure | |||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||
| Financing Activities | |||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||
| interest | |||||||
| cash flow from financing | |||||||
| cash and cash equivalents | |||||||
| cash | 0 | 0 | -442,244 | -457,832 | 897,928 | 2,148 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | -442,244 | -457,832 | 897,928 | 2,148 | 0 |
therapeutic frontiers limited Credit Report and Business Information
Therapeutic Frontiers Limited Competitor Analysis
Perform a competitor analysis for therapeutic frontiers limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
therapeutic frontiers limited Ownership
THERAPEUTIC FRONTIERS LIMITED group structure
Therapeutic Frontiers Limited has no subsidiary companies.
Ultimate parent company
THERAPEUTIC FRONTIERS LIMITED
09029209
therapeutic frontiers limited directors
Therapeutic Frontiers Limited currently has 1 director, Dr Ross Walton serving since May 2014.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Ross Walton | United Kingdom | 45 years | May 2014 | - | Director |
P&L
March 2021turnover
1.1m
+73%
operating profit
-323k
0%
gross margin
27.1%
-20.15%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2021net assets
-41.2k
-1.15%
total assets
301.2k
-0.02%
cash
0
0%
net assets
Total assets minus all liabilities
therapeutic frontiers limited company details
company number
09029209
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
May 2014
age
10
accounts
Micro-Entity Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
18 field lane, london, TW11 9AW
last accounts submitted
March 2021
therapeutic frontiers limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to therapeutic frontiers limited.
therapeutic frontiers limited Companies House Filings - See Documents
| date | description | view/download |
|---|
